1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Francisella Tularensis Infections - Pipeline Review, H2 2015

Francisella Tularensis Infections - Pipeline Review, H2 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 45 pages

Francisella Tularensis Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Francisella Tularensis Infections - Pipeline Review, H2 2015’, provides an overview of the Francisella Tularensis Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Francisella Tularensis Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Francisella Tularensis Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Francisella Tularensis Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Francisella Tularensis Infections - Pipeline Review, H2 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Francisella Tularensis Infections Overview 6
Therapeutics Development 7
Pipeline Products for Francisella Tularensis Infections - Overview 7
Pipeline Products for Francisella Tularensis Infections - Comparative Analysis 8
Francisella Tularensis Infections - Therapeutics under Development by Companies 9
Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes 10
Francisella Tularensis Infections - Pipeline Products Glance 11
Early Stage Products 11
Francisella Tularensis Infections - Products under Development by Companies 12
Francisella Tularensis Infections - Products under Investigation by Universities/Institutes 13
Francisella Tularensis Infections - Companies Involved in Therapeutics Development 14
Aradigm Corporation 14
Arno Therapeutics, Inc. 15
EpiVax, Inc. 16
Tetraphase Pharmaceuticals Inc. 17
Francisella Tularensis Infections - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AR-12 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ciprofloxacin hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
francisella tularensis [strain SchuS4] vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
SRI-011225 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
TP-271 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
tularemia vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
TuliVax - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Francisella Tularensis Infections - Recent Pipeline Updates 38
Francisella Tularensis Infections - Dormant Projects 40
Francisella Tularensis Infections - Dormant Projects 40
Francisella Tularensis Infections - Discontinued Products 41
Francisella Tularensis Infections - Product Development Milestones 42
Featured News and Press Releases 42
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 42
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 42
Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Francisella Tularensis Infections, H2 2015 7
Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Francisella Tularensis Infections - Pipeline by Aradigm Corporation, H2 2015 14
Francisella Tularensis Infections - Pipeline by Arno Therapeutics, Inc., H2 2015 15
Francisella Tularensis Infections - Pipeline by EpiVax, Inc., H2 2015 16
Francisella Tularensis Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 17
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Francisella Tularensis Infections Therapeutics - Recent Pipeline Updates, H2 2015 38
Francisella Tularensis Infections - Dormant Projects, H2 2015 40
Francisella Tularensis Infections - Discontinued Products, H2 2015 41

List of Figures
Number of Products under Development for Francisella Tularensis Infections, H2 2015 7
Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 11
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Top 10 Targets, H2 2015 19
Number of Products by Stage and Top 10 Targets, H2 2015 19
Number of Products by Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Top 10 Routes of Administration, H2 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23
Number of Products by Top 10 Molecule Types, H2 2015 25
Number of Products by Stage and Top 10 Molecule Types, H2 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the ...

Global Feed Antibiotics Market

December 2016 $ 4250

Acetic Acid Markets In China

January 2017 $ 4000

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.